Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/20/2025

Management of Vaginal Candidiasis Not Responding to Oral Fluconazole

Diagnostic Considerations

  • The Infectious Diseases Society of America recommends verifying the presence of yeast or hyphae using wet-mount preparation with saline and 10% potassium hydroxide 1
  • The Infectious Diseases Society of America suggests checking vaginal pH (normal is 4.0-4.5 in candidiasis) 1
  • Obtaining vaginal cultures to identify the specific Candida species, particularly to rule out non-albicans species like C. glabrata, is recommended by the Infectious Diseases Society of America 2

Treatment Algorithm for Fluconazole-Resistant Vaginal Candidiasis

  • The Infectious Diseases Society of America strongly recommends topical intravaginal boric acid in gelatin capsules, 600 mg daily for 14 days, as the first alternative treatment option 1, 2
  • The Infectious Diseases Society of America recommends nystatin intravaginal suppositories, 100,000 units daily for 14 days, as a second-line alternative therapy 1, 3
  • The Infectious Diseases Society of America suggests topical 17% flucytosine cream alone or in combination with 3% amphotericin B cream daily for 14 days as a third-line alternative therapy 1, 2

Special Considerations

  • The Infectious Diseases Society of America notes that C. glabrata often doesn't respond to azoles including voriconazole 2
  • Boric acid is particularly effective for C. glabrata infections, according to the Infectious Diseases Society of America 1, 2
  • The Infectious Diseases Society of America recommends considering maintenance therapy after achieving control with one of the above regimens 1
  • For recurring vulvovaginal candidiasis (≥4 episodes in 12 months), the Infectious Diseases Society of America suggests using 10-14 days of induction therapy followed by fluconazole 150 mg weekly for 6 months 1, 2

Common Pitfalls and Caveats

  • The Infectious Diseases Society of America warns that failure to identify the causative species can lead to ineffective treatment 1, 2
  • Not all Candida species respond to the same treatments - C. glabrata and C. krusei are often fluconazole-resistant, according to the Infectious Diseases Society of America 2
  • Compounded medications (boric acid capsules, flucytosine cream) require a specialized pharmacy, as noted by the Infectious Diseases Society of America 2
  • Without maintenance therapy after successful treatment, recurrence rates of 40-50% can be expected, according to the Infectious Diseases Society of America 2
  • Azole-resistant C. albicans infections are rare but can develop following prolonged azole exposure, as reported by the Infectious Diseases Society of America 2